Merck announces that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has unanimously recommended Capvaxive (21-valent pneumococcal conjugate vaccine) for pneumococcal vaccination of adults 65 years of age and older. This recommendation also includes guidelines for adults 19 to 64 years of age under certain medical conditions.

This recommendation also includes guidelines for adults aged 19 to 64 under certain medical conditions.

Capvaxive is designed to prevent invasive disease and pneumonia caused by several strains of Streptococcus pneumoniae.

Copyright (c) 2024 CercleFinance.com. All rights reserved.